Matsuoka H, Seo Y, Ohshiro T, Adachi E, Nagamine S, Miyazaki N, Shiromizu A, Baba H, Kounoe S, Saito T
Clinical Research Institute, National Kyushu Cancer Center.
Gan To Kagaku Ryoho. 1995 Feb;22(3):383-8.
In 4 out of 5 patients given 400 mg orally 5'-DFUR before surgery, intratumor 5-FU concentration showed over 150 ng/g. The concentration of either 5-FU or 5'-DFUR in the portal and peripheral blood of these patients exceeded the limits of assay. 5-FU concentration in peripheral blood was less than 0.05 micrograms/ml. White blood cell and platelet counts in the patients given 1,600 mg/day (no administration for 2 days/week) of 5'-DFUR for one month were essentially the same with those at the time of start of the treatment. Two of three patients showed minor response following the treatment with 5'-DFUR. Thus, administration of 1,600 mg/day of 5'-DFUR may be considered as an effective treatment of fluopyrimidine against advanced cancer. For the prediction of gastrointestinal side effect, assay of the 5-FU concentration in the portal blood seemed to be useful.
在术前口服400mg 5'-DFUR的5例患者中，有4例肿瘤内5-FU浓度超过150ng/g。这些患者门静脉血和外周血中5-FU或5'-DFUR的浓度超出了检测限。外周血中5-FU浓度低于0.05μg/ml。给予1600mg/天（每周停药2天）的5'-DFUR治疗1个月的患者，其白细胞和血小板计数与治疗开始时基本相同。3例患者中有2例在接受5'-DFUR治疗后出现轻微反应。因此，每天给予1600mg的5'-DFUR可被视为氟嘧啶对晚期癌症的有效治疗方法。对于胃肠道副作用的预测，检测门静脉血中5-FU浓度似乎是有用的。
